PATENT CLAIM ANALYSIS

Application Number: 15750471
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["514", "043000"]

Abstract:
The present invention relates to mannose derivatives of formula (I): wherein R 1  represents H, CO—(C 1 -C 6 )-alkyl or CO-alkylaryl, Y represents a single bond, CH 2 , O, NR 3 , S, A represents O, NH or S, X represents H and X′ represents OH or X and X′ taken together with the carbon atom bearing them form a CO group, R 2  represents H, a linear or branched (C 1 -C 6 )-alkyl or CF 3 , R 3  represents H, a C 1 -C 6  alkyl, a CO—(C 1 -C 6 )-alkyl, CF 3  or COCF 3 , and R is as described in claim  1.    The mannose derivatives of formulae (I) are useful for treating pathologies associated with the presence of adherent  Escherichia coli  (AEC), in particular inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis; a urinary tract infection, in particular painful bladder syndrome and cystitis, more particularly interstitial cystitis; irritable bowel syndrome; metabolic diseases such as metabolic obesity, diabetes, hypercholesterolemia; autoimmune inflammatory diseases; and colorectal cancer, in particular colon cancer.

Claim (Index 16):
A kit comprising:\n the composition of  claim 11  or  12 , and a second composition comprising another therapeutic compound, as a combination product for simultaneous, separate and staggered use for treating pathologies caused by  Escherichia coli  and mediated by interactions between  Escherichia coli  lectins and host cell surface glycans, in particular pathologies caused by  Escherichia coli  and mediated by interactions between  Escherichia coli  FimH adhesin and host cell surface glycans, such as: an inflammatory bowel disease, in particular Crohn's disease; a urinary tract infection, in particular painful bladder syndrome and cystitis, more particularly interstitial cystitis; an irritable bowel syndrome; a metabolic disease such as metabolic syndrome, obesity, diabetes, hypercholesterolemia; autoimmune inflammatory diseases including Berger's disease, Graves' disease, Hashimoto's thyroiditis, the primary myxedema, celiac disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, primary biliary cirrhosis, primary sclerosing cholangitis, the autoimmune hemolytic anemia, pernicious anemia (pernicious anemia), lupus erythematosus, CREST syndrome, type 1 diabetes, scleroderma, pemphigus vulgaris, pemphigoid oily, the epidermolysis Bullosa acquired, dermatitis herpetiformis, myasthenia, Lambert-Eaton myasthenic syndrome, polymyositis, Sj\u00f6gren's syndrome, multiple sclerosis, rheumatoid arthritis, Grave's disease and psoriasis; and colorectal cancer, in particular colon cancer.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 88.0
- Lexical Diversity: 2.09346
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14416529', '15113986', '13437491', '12594495', '13180144']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7506891420627256
- 35 USC 102 Novelty (BERT): 0.5451024055349215
- Combined Prediction Score: 0.7301304684099452
- Mean Citation Score: 334.753958
- Max Citation Score: 387.36984
- Similarity Product: 278.68228600007063

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test